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ABSTRACT 
Objective: In the present work, the main objective was to develop bilayer extended release matrix tablets of etoricoxib by providing a loading dose 
followed by maintenance dose that expected to improve the therapeutic efficacy of the medication with less toxic effect.  
Methods: Bilayer tablets of etoricoxib was developed successfully with the meticulous proportion of release controlling Hydroxy propyl methyl cellulose 
K100 (HPMC K100) and lactose. The tablets were prepared by wet granulation technique. Granules for immediate layer and extended layer for different 
formulations were prepared separately. The formulations were developed and evaluations were performed to examine the parameters that affect the in vitro 
performance of the tablets. The drug-excipient compatibility was ensured by Fourier transform infrared spectroscopy (FTIR) study. 
Results: The values of physical parameters of all formulations were found within appreciable limit. Formulation containing HPMC K 100 and lactose 
in the proportion of 2:1 in the extended release layer was able to release 26.22% of drug in 15 min and shown a steady release of drug for an 
extended period of 12 h. The dissolution data was put in Korsemeyer–Peppas model in order to find out n value, which describes the drug release 
mechanism. The n-value of different formulations were found to be variable. The Fourier transform infrared spectroscopy (FTIR) study revealed 
absence of any other new peaks and also no differences in the positions of the absorption bands in the bilayer tablet F8 that indicate the lack of 
significant interactions between etoricoxib and other excipients. 
Conclusion: It had been concluded that once daily immediate-and extended release bilayer tablet of etoricoxib can be formulated with profound 
physical characteristics and dissolution properties. This resulted in reducing the daily dose and thus minimise the cardiovascular toxicity of etoricoxib. 
Keywords: Etoricoxib, Bilayer technology, Once daily tablet, Release kinetics 




Etoricoxib; (5-chloro-2-[6-methyl pyridin-3-yl]-3-[4-methyl sulfonyl 
phenyl] pyridine) is a selective second generation cyclooxygenase-2 
inhibitor administered orally as an analgesic and anti-inflammatory drug 
[1, 2]. However, the drug possesses a saturation solubility of 78.48±1.47 
μg/ml. This leads to formulation problems and limit its therapeutic 
efficacy by delaying the rate of absorption and the onset of action [3].  
The recommended dose for etoricoxib is between 60 and 120 
mg/day. It has an estimated logP of 3.14 and pKa of 4.6. 
Pharmacokinetic studies reveal that despite of a potent drug for 
osteoarthritis, it suffers from severe cardiovascular toxicity issues. 
The cardiovascular risks of etoricoxib may increase with dose and 
duration of exposure. Therefore the possible lowest effective daily 
dose should be developed to combat this problem [4]. 
Recently, multilayer tablets have been gaining importance for enhancing 
the formulation efficacy and improving the patient compliance by 
reducing the dosing burden [5, 6]. Moreover, the release profiles can be 
modified using multiple compatible components in the multilayer tablet 
strategy [7, 8]. In bilayer tablet technology, one is for immediate-release 
layer and the other is for modified-release layer. The immediate-release 
layer will disintegrate rapidly and transiently after oral administration, 
thus providing enough drug for immediate onset of action while, on the 
other hand, the modified-release part will dissolve slowly in the 
gastrointestinal tract to maintain a steady drug release. 
The rationality of the present study was to explore the feasibility of 
developing a bilayer tablet strategy, a once daily immediate-and 
extended-release formulation of etoricoxib. The fast release of drug 
from the immediate release layer achieve the quick onset and the 
extended release of drug capable of maintaining the therapeutic 
level. This resulted in reducing the daily dose and thus minimise the 
cardiovascular toxicity of etoricoxib. In this study the formulations 
were developed, and evaluations were performed to examine the 
parameters that affect the in vitro performance of the tablets. 
A novel once daily immediate-and extended-release drug delivery 
system of etoricoxib was developed for the following reasons: 1) To 
synchronize drug delivery to achieve quick onset of action in severe 
pain; 2) To prolong therapeutic effect by continuously releasing the 
medication over an extended period of time after administration of a 
single dose; 3) To minimize the frequency of drug administration by 
developing a once daily therapy; 4) Improved therapy can be 
provided as the drug exerts its action at a time when it is needed 
most and dose related side effects could be minimized; 5) Patient 
convenience and compliance could be achieved. 
MATERIALS AND METHODS 
Materials 
Drug etoricoxib was obtained as a gift sample from Hetero drugs, Baddi, 
India. HPMC K 100 M, HPMC E5 and croscarmellose sodium were 
procured from Colorcon Asia Pvt. Ltd., Goa, India. Microcrystalline 
Cellulose, Lactose, starch, Talc and magnesium stearate were purchased 
from Loba Chemie Pvt. Ltd., Mumbai, India. Poly Vinyl Pyrollidone was 
bought from SD Fine Chem Limited, Mumbai, India. The materials that 
were of AR/lR grade and were used as supplied by the manufacturer 
without further purification or investigation. 
Methods 
Preparation of bilayer tablet 
The tablets were prepared by wet granulation technique. Granules 
for immediate layer and extended layer for different formulations 
were prepared separately. The composition of two layers of tablets 
are depicted in table 1 [9]. 
Extended release layer of etoricoxib  
The granules of the extended release layer were prepared by the wet 
granulation method. After being grinded and sifted through sieve no 
60, the drug was mixed thoroughly with other inactive ingredients 
excluding talc and subsequently passed through a 16-mesh screen to 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 11, Issue 5, 2019 
Mishra et al. 
Int J App Pharm, Vol 11, Issue 5, 2019, 230-235 
231 
blend the ingredients uniformly. The mixture was granulated using 
3% (w/w) PVP in a 90% ethanol solution as binder and then pressed 
through a 20-mesh screen to prepare wet granulates. After drying at 
45 °C for 1 h in an oven, the granules were sieved through an16-
mesh screen and then mixed with talc for the following table ting 
process. 
Immediate release layer of etoricoxib  
The granules of the immediate release layer containing etoricoxib 
and other excipients (table 1) were fabricated by a similar 
procedure described above. The superdisintegrant and talc of 
specified amount were added after granulation.  
Preparation of bilayer matrix tablets  
The bilayer tablets were fabricated with a single-punch tablet machine 
(Cadmach-Ahmedabad) via a single compaction method. Briefly, the 
weighed granules were sequentially fed manually into the die cavity 
and then compressed into tablets under pressure between 3 and 15 
kg/cm2
 
. Table 1 exhibits the detailed formula compositions for the 
bilayer tablets. The size batch was 100 tablets for each formulation. 
Table 1 Formulation composition for bilayer tablet 
Excipients Formulations  
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Extended release layer 
Etoricoxib (mg) 60 60 60 60 60 60 60 60 60 60 
HPMC K100 (mg) 60 60 60 60 45 45 60 60 30 30 
Lactose (mg) - - - - 45 45 30 30 60 60 
PVP (%) 3 3 3 3 3 3 3 3 3 3 
Talc (%) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Immediate release layer 
Etoricoxib (mg) 30 30 30 30 30 30 30 30 30 30 
HPMC E5 30 - - - - - - - - - 
Lactose (mg) - - 30 - 30 30 30 30 30 30 
MCC (mg) - 30 - - - - - - - - 
Starch (mg) - - - 30 - - - - - - 
Croscarmellose Sodium (%) 3 3 3 3 3 4 3 4 3 4 
PVP (%) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc (%) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
*
 
PVP-poly vinyl pyrollidone; HPMC-Hydroxy propyl methyl cellulose; MCC-micro crystalline cellulose 
Evaluation of etoricoxib bilayer tablet  
Flow property of granules 
The flow characteristics of the granules of both immediate and extended 
layer were examined through determining inter particle porosity, 
Hausner ratio and Carr’s index [10, 11]. All the determinations were 
done in triplicate and the mean values were reported.  
Physical parameters of bilayer tablets 
Weight variation, thickness and diameter uniformity, hardness and 
friability of different batches of bilayer tablets were performed. 
Twenty tablets were selected randomly from the lot and weighed 
individually by using digital balance and the weight variation of 
individual tablet from its mean value was calculated. The thickness 
and diameter of the tablets in mm was measured by vernier calliper 
scale. The hardness of the tablets (kg/cm2) was determined in 
triplicate using Monsanto Hardness Tester [12]. The friability of 
tablets was determined using Roche Friabilator. It is expressed in 
percentage (%). Twenty tablets were initially weighed (Wo) and 
transferred into friabilator. The friabilator was operated at 25 rpm 
for 4 min or run up to 100 revolutions. The final weight of the tablet 
(Wt
F = [1 − Wt
W0
] X100 ---------------------------- (1) 
) was measured. The % friability was calculated by, 
Content uniformity 
Three tablets were selected randomly from each batch and triturate 
by mortar and pestle. The powder equivalent to 100 mg of etoricoxib 
was taken into three different 100 ml volumetric flasks. To each of it, 
100 ml of ethanol was poured, sonicated for 10 min and kept for 24 
h away from light. The solutions were filtered through whattman 
filter paper and the filtrate was analysed in UV-Visible 
spectrophotometer at 282 nm. The unknown concentration of the 
drug was determined using standard calibration curve. 
In vitro drug release study  
The release of etoricoxib from different formulations was monitored 
using standard USP dissolution apparatus No. 2 (Paddle method). 
Three tablets from each formula were individually tested. The 
dissolution was performed in 900 ml of Phosphate buffer pH 7.4 for 
12 hour. The stirring rate was 50 rpm±1 and the temperature was 
maintained at 37±0.5 °C. Aliquots of 5 ml were withdrawn manually 
at predetermined time points till 12 h and replaced with same 
quantity of fresh preheated (at 37 °C) dissolution medium. Samples 
were measured spectrophotometrically at λ= 282 nm. The amount 
released was calculated from the regression line of the standard 
calibration curve developed in the same medium [13, 14].  
Kinetics of drug release 
To analyze the drug release rate kinetics and mechanism of drug 
release from the bilayer tablets, the in vitro dissolution studies data 
was fitted into Zero order, First order, Higuchi, Hixon crowell and 
Korsmeyer Peppas models. Co-relation coefficient (R2
FTIR-ATR spectroscopy  
) value were 
the determinant for the best-fit of the model [11]. 
FTIR spectra were recorded at room temperature in the mid-IR 
range (500–4000 cm-1) on a Bruker Alfa FTIR spectrometer 
equipped with a Bruker ZnSe ATR accessory with a single reflection 
ZnSe crystal. Each spectrum was averaged over 24 scans with a 
resolution of 4 cm-1
RESULTS AND DISCUSSION 
. A background scan was recorded prior to the 
measurement and subtracted from the sample spectra. For each 
sample, the initial aqueous solution was placed directly on the ATR 
ZnSe and the spectrum recorded. The ATR correction to each 
spectrum was applied using the OPUS software. The spectra were 
normalized to the same area and compared to each other. To get 
some insights into the conformational differences of the investigated 
samples, some spectral ranges were analyzed.  
Evaluation of immediate and extended layer granules 
Flow properties of immediate release layer granules and 
extended release layer granules 
The immediate layer granules and extended layer granules of all 
formulations were determined and the results were depicted in 
table 2. The result of flow property study revealed that the granules 
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have good flowability against the flowability of drug that ensure the 
uniform flow of the granule from hopper to the die cavity as a result 
of reduced cohesiveness. Result of all the flow parameters were 
obtained within the permissible limit [15]. 
 





























Extended Release Layer (Limit) Immediate release layer (Limit) 
0-1 0-1 0-1.2 <1.2 <40 0-1 0-1 0-1.2 <1.2 <40 
Drug 0.232 0.370 1.608 1.595 37.297 - - - - - 
F1 0.469 0.518 0.202 1.104 9.459 0.453 0.519 0.281 1.146 12.717 
F2 0.469 0.518 0.202 1.104 9.459 0.458 0.520 0.260 1.135 11.923 
F3 0.469 0.518 0.202 1.104 9.459 0.576 0.611 0.099 1.061 5.728 
F4 0.469 0.518 0.202 1.104 9.459 0.764 0.891 0.187 1.166 14.254 
F5 0.972 1.137 0.149 1.170 14.512 0.627 0.683 0.131 1.089 8.199 
F6 0.972 1.137 0.149 1.170 14.512 0.638 0.721 0.180 1.130 11.512 
F7 0.472 0.507 0.146 1.074 6.903 0.627 0.683 0.131 1.089 8.199 
F8 0.472 0.507 0.146 1.074 6.903 0.638 0.721 0.180 1.130 11.512 
F9 0.732 0.807 0.127 1.102 9.294 0.627 0.683 0.131 1.089 8.199 
F10 0.732 0.807 0.127 1.102 9.294 0.638 0.721 0.180 1.130 11.512 
n= 3, All determinations were done in triplicate and the mean values are reported.  
 
Evaluation of immediate and extended release bilayer tablets 
The physical parameters for all the formulations is shown in table 3. 
All the tablets passed weight variation test as the average % weight 
variation were within the pharmacopoeia limits of ±7.5%. Tablet 
mean thickness (n=5) were almost uniform in all the formulations 
and values ranged from 3.5±0.03 to 4.5±0.06. Tablet mean diameter 
(n=5) were also found to be uniform all the ten formulations i.e. 7.9 
mm. The standard deviation values indicated that all the 
formulations were within the range [9]. 
 
Table 3: Evaluation of bilayer tablet formulations 
Formulation F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Average weight (mg) 182 180 182 182 252 258 253 261 254 259 
Weight variation (%) ±1.56 ±1.39 ±2.07 ±1.91 ±2.30 ±2.27 ±2.01 ±2.15 ±2.03 ±2.21 




















Hardness (kg/cm2 7.0 )# 6.1 6.0 6.2 5.1 4.7 6.1 5.4 6.0 6.1 
Friability (%) 0.187 0.243 0.142 0.174 0.183 0.119 0.324 0.286 0.232 0.327 




















All the values are expressed as mean±SD, where *n=5and #n=3 
 
The mean hardness values (n=3) were measured for all the 
formulations using a Monsanto hardness tester. The results are 
tabulated in table 3. The hardness values ranged from 4.7 to 7.0 
kg/cm2
  
. The values of friability test were given in table 3. The 
percent friability for all the formulations was below 1%, indicating 
that the friability is within the prescribed limits. The results of 
friability test indicate that the tablets possess good mechanical 
strength [16]. 
 
Fig. 1: Comparative n in vitro dissolution profile of F1, F2, F3 and F4 
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Content uniformity 
The percent drug content value of etoricoxib was within 98.86±1.84 to 
100.05±1.39. The results within range indicate uniformity of mixing. 
In vitro drug release study 
The comparative dissolution profile of F1 to F4 and F5 to F10 are 
depicted in fig. 1 and fig. 2 respectively. In the formulation F1 to F4 it was 
observed that for the formulation containing lactose had shown a steady 
release rate profile as compared to formulation containing HPMC E5, 
Micro crystalline cellulose and starch. From formulation F1, F2 and F3 
the drug was released in a slower rate not able to get a dissolution of 
30% even in the first hour. It is due to the binding ability of HPMC E5, 
Micro crystalline cellulose and starch that retard the drug dissolution.  
From F5 to F10 the extended layer contains HPMC K100 with 
different proportion of lactose whereas the immediate layer 
contains only lactose. Cross carmelose sodium was used as 
superdisintegrant in the immediate layer. It was observed from the 
dissolution profile that more than 30% of drug released in the first 
15 min from F5, F6, F9 and F10. The drug release was successfully 
extended up to 5hr, 6hr, 8hr and 9hr for F9, F10, F6 and F5 
respectively. F7 was able to release 22.59% of drug in 15 min and 
shown a steady release of drug for an extended period of 12 h. 
Similarly F8 was able to release 26.22% of drug in 15 min and 
shown a steady release of drug for an extended period of 12 h (fig. 1 
and fig. 2). From the above observation we concluded that the drug 
release from all the formulations were extended for a longer period 
of time [17]. 
 
 
Fig. 2: Comparative in vitro dissolution profile of F5, F6, F7, F8, F9 and F10 
 
From the dissolution profile of all formulation it had been observed 
that F7 and F8 are suitable for once daily immediate-and extended 
release bilayer tablet of etoricoxib. In all formulation the rate of 
release was different due to their differences in composition. The 
reason behind the variation in drug release kinetics were based 
upon the nature of ingredients used [10, 11]. 
HPMC K100 had faster drug diffusion from the polymeric matrix 
with increase in the water uptake. The high water uptake leads 
to considerable swelling of the polymer matrix that caused the 
drug to diffuse out from polymer matrix at a faster rate. HPMC 
K100 had uniform gelling and binding effect because it was 
easily gelled in presence of aqueous solvent. It plays a significant 
role in the design of a controlled release product thus it showed 
better sustained release. The drug diffusion patterns of all the 
formulations were also depended upon the viscosity of the 
polymer used. By increasing the viscosity of the system which 
increased the chances of availability of active binding sites in the 
polymeric chain [18]. 
In cross carmelose sodium, the cross-linking reduces 
water solubility while still allowing the material to swell (like 
a sponge) and absorb many times its weight in water. As a result, it 
provides superior drug dissolution and disintegration 
characteristics, subsequently bringing the active ingredients into 
better contact with bodily fluids. 
 
Table 4: Various parameters of the model equations of the in vitro release kinetics 
Formulation 
code 
Zero order First order Higuchi model Hixon crowell  
model 
Korsmeyer-peppas model 
r K2 r0 K2 r1 K2 rH K2 rHC K2 n P 
F1 0.9692 8.0947 0.9776 0.0981 0.9812 29.861 0.8883 0.226 0.9921 7.4353 1.6299 
F2 0.9176 4.2599 0.8441 0.0293 0.8275 14.831 0.9527 0.1503 0.9121 8.3483 1.0593 
F3 0.9285 3.1586 0.9629 0.0231 0.9727 11.852 0.8474 0.0935 0.9754 4.0870 0.656 
F4 0.7632 3.8296 0.855 0.0271 0.8749 15.033 0.5695 0.1422 0.8164 8.1433 1.4678 
F5 0.9025 6.9481 0.803 0.2437 0.9776 25.747 0.8543 0.134 0.9854 1.8750 0.5797 
F6 0.9045 6.837 0.958 0.232 0.9646 23.832 0.8837 0.1243 0.9561 1.6018 0.4523 
F7 0.9323 5.7498 0.9113 0.1055 0.9874 24.104 0.8521 0.1227 0.9911 2.6062 0.7356 
F8 0.8946 5.6064 0.9828 0.1072 0.9807 23.913 0.8232 0.1161 0.9949 2.3768 0.693 
F9 0.9763 13.946 0.8606 0.3318 0.9909 38.746 0.9346 0.2828 0.9903 1.9165 0.7599 
F10 0.9451 9.5277 0.8653 0.2604 0.9885 29.00 0.9011 0.1824 0.9916 1.7018 0.553 
K0, K1, KH, KHC are the rate constants for Zero Order, First Order, Higuchi Model, Hixon crowell Model respectively, r2
 
 = correlation co-efficient 
Taking different data’s from the kinetic profiles, we got different 
kinetic models belonging to different equations. There was a 
comparison of all the R2 value of Zero Order, First Order, Higuchi 
equation and Hixon Crowell equation of F1 to F10 depicted in table 
4. From this table we got that in all the formulations the correlation 
coefficient values were variable. All the formulation followed 
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Higuchi model as the R2
 
 value found to be maximum except F2 and 
F8. The data obtained was also put in Korsemeyer–Peppas model in 
order to find out n value, which describes the drug release 
mechanism. The n-value of different formulations were found to be 
variable as depicted in and the drug release mechanism was 
predicted accordingly table 5. 
Table 5: Release mechanism of drug from different formulation 
Formulation Diffusion exponent ‘n’ Release mechanism 
F1 1.63 Super case II transport 
F2 1.06 Super case II transport 
F3 0.66 Non-Fickian transport 
F4 1.47 Super case II transport 
F5 0.58 Non-Fickian transport 
F6 0.45 Non-Fickian transport 
F7 0.74 Non-Fickian transport 
F8 0.69 Non-Fickian transport 
F9 0.76 Non-Fickian transport 
F10 0.55 Non-Fickian transport 
 
 
Fig. 3: FTIR study. a) Etoricoxib; b) HPMC K100; c) Lactose; d) F8 
 
FTIR study 
FT-IR studies were done to find out the possible intermolecular 
interactions between the etoricoxib and other ingredients. The 
characteristic peaks of etoricoxib, HPMC K100, lactose and F8 are 
depicted in fig. 3. Absence of any other new peaks and also no 
differences in the positions of the absorption bands in the bilayer 
tablet F8 indicate the lack of significant interactions between 
etoricoxib and other excipients [19]. 
CONCLUSION 
Bilayer tablets of etoricoxib was developed successfully with 
meticulous proportion of release controlling HPMC K100 and 
lactoseThe n-value of different formulations obtained from 
Korsemeyer–Peppas model were found to be variable. The FTIR study 
revealed absence of new peaks and also no differences in the positions 
of the absorption bands in the bilayer tablet F8 that indicate the lack of 
significant interactions between etoricoxib and other excipients. 
Hence it had been concluded that F7 and F8 are suitable for once daily 
immediate-and extended release bilayer tablet of etoricoxib. 
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